Compare First Trust NASDAQ Smart Grid ETF (GRID) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust NASDAQ Smart Grid ETF vs Organon & Co. Common Stock — how do they compare? First Trust NASDAQ Smart Grid ETF trades at $171.92 (market cap $12.08B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: First Trust NASDAQ Smart Grid ETF is far larger — about 3.3× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while First Trust NASDAQ Smart Grid ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Trust NASDAQ Smart Grid ETF for 14 Days and Organon & Co. Common Stock for 0 Days on average.
| GRID | OGN | |
|---|---|---|
Market Cap | $12.08B | $3.61B |
Volume | 430,482 | 1,808,049 |
Sector | Sector/Thematic | Health |
52-Week High | $199.80 | $13.81 |
52-Week Low | $146.51 | $5.70 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | — | $11.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GRID trades at $179.25, up 0.31% on the day, with a bearish technical signal from moving averages and neutral oscillators. The stock is positioned in the smart grid infrastructure sector, benefiting from AI-driven power buildout investments. Recent news highlights its exposure to infrastructure modernization and AI energy demand, though key financial ratios are not disclosed in the provided data.
Outlook is mixed: technicals suggest caution, but thematic tailwinds from AI infrastructure spending offer growth potential. Risks include sector competition and execution challenges. Investors should weigh near-term technical weakness against long-term infrastructure investment trends.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About First Trust NASDAQ Smart Grid ETF
First Trust NASDAQ Smart Grid Infrastructure ETF seeks to track companies involved in smart grid and electricity infrastructure. Its holdings include businesses related to power networks, energy management, and grid technologies.
Read more on GRID →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
